New once-daily SPIOLTO® is well tolerated2

  • SPIOLTO® is generally well tolerated with an adverse event profile similar to the well-known profiles of the monotherapies1–4

  • Most adverse events were mild or moderate with no new safety risks seen beyond the known effects of the ingredients1–4

  • The proportion of patients who discontinued due to an adverse reaction was lower for SPIOLTO® compared to SPIRIVA® or STRIVERDI®2

  • SPIOLTO®: with no additional safety risks